# Positron emission tomography and perfusion weighted imaging in the detection of brain tumors recurrence

## A meta-analysis

*Tareef S. Daqqaq,* MBBS, Facharzt, **Ayman S. Alhasan,** MBBS, DES.

## ABSTRACT

**الأهداف**: تقييم ومقارنة دقة التشخيص وحساسية ونوعية PWI و PET في التمييز بين التغييرات المرتبطة بالعلاج وتكرار الورم.

**المنهجية**: أجرينا مراجعة منهجية لقواعد بيانات PubMed و Embase و Web of Science ومكتبة كوكرين و CINAHL منذ بداية قاعدة البيانات حتى أغسطس 2021م للمقالات ذات الصلة. قمنا بتطبيق معايير إدراج واستبعاد خاصة لاختيار الدراسات المؤهلة. قمنا باستخدام أداة تقييم جودة دقة التشخيص (QUADAS–2) لتقييم مخاطر التحيز والجودة المنهجية للدراسات المؤهلة. من الدراسات المشمولة، قمنا بتقدير نسبة المعدل (RR) للدقة المجمعة والحساسية والنوعية وفترات الثقة المقابلة (CIs) لكل من PWI و PET.

**النتائج**: تتألف المراجعة المنهجية والتحليل التلوي من 14 دراسة بحثية، مع ما مجموعه 542 مريضاً. على الرغم من أن PET كشفت عن دقة وحساسية أعلى بشكل معتدل عند مقارنتها بـ PWI (RR: 0.94، 95% CI 0.86–1.02 و RR: 0.95 95% CI 0.85–1.06 ، على التوالي ) ، لم يكن الاختلاف ذا دلالة إحصائية (0.05<*p*) . وبالمثل، أظهر PWI خصوصية أعلى بشكل معتدل بالمقارنة مع PET (RR: 1.10، 95% CI 0.98–1.23) ولكن لم يتم اكتشاف فرق معتد به إحصائيًا بين الطريقتين (0.05<*p*) . ومن المثير للاهتمام، أننا كشفنا أن 18F–FET–PET كان أكثر كفاءة بشكل ملحوظ من PWI من حيث الدقة ( 0.72–0.93 CI 95%، 0.82 :RR ) والحساسية ( RR: 0.72، 95% CI 0.62–0.83 ) (0.05<*p*).

**الخلاصة**: أسفر كل من PET و PWI عن أداء تشخيصي جيد في التمييز بين التغييرات المرتبطة بالعلاج من تكرار الورم، ولا يبدو أن أيًا من الأسلوبين متفوق.

**Objectives:** To assess and compare the diagnostic accuracy, sensitivity and specificity of perfusion-weighted imaging (PWI) and positron emission tomography (PET) in distinguishing between treatment-related changes and tumor recurrence.

**Methods:** We carried out a systematic review of PubMed, Embase, Web of Science, the Cochrane Library, and CINAHL databases from database inception until August 2021 for pertinent articles. Particular inclusion and exclusion criteria were applied to select the eligible studies. The Quality Assessment of Diagnostic Accuracy tool was used to assess the risk of bias and methodological quality of the eligible studies. From the included studies, the rate ratio (RR) of pooled accuracy, sensitivity, specificity and their corresponding confidence intervals (CIs) were estimated for both PWI and PET.

**Results:** The systematic review and meta-analysis comprised 14 research studies, with a total of 542 patients. Although PET revealed a moderately higher accuracy and sensitivity when compared to PWI (RR: 0.94, 95% CI 0.86-1.02 and RR: 0.95 95% CI 0.85-1.06, respectively), the difference was not statistically significant (*p*>0.05). Similarly, while PWI demonstrated a moderately higher specificity when compared to PET (RR:1.10, 95% CI 0.98-1.23) but. However, no statistically significant difference between the 2 modalities was detected (*p*>0.05). Interestingly, we revealed that 18F-FET-PET was significantly more efficient than PWI in terms of accuracy (RR: 0.82, 95% CI 0.72-0.93) and sensitivity (RR: 0.72, 95% CI 0.62-0.83) (*p*>0.05).

**Conclusion:** Both PET and PWI yielded good diagnostic performance in distinguishing treatment-related changes from tumor recurrence, and neither modality seemed to be superior.

PROSPERO ID: CRD42021288160

*Address correspondence and reprint request to: Dr. Ayman S. Alhasan, Department of Radiology, College of Medicine, Taibah University, Al Madinah Al Munawwarah, Kingdom of Saudi Arabia. E-mail: ahasan@taibahu.edu.sa*
*ORCID ID: https://orcid.org/0000-0001-8879-4017*

Brain tumors occur when abnormal and uncontrolled cell division appears in the brain. Nowadays, non-cancerous (benign) tumors and cancerous (malignant) tumors are the 2 groups of tumors recognized worldwide.[1] Brain tumors can also be categorized as primary tumors, starting in the brain, and secondary tumors, also known as brain metastasis tumors, which most frequently have spread to the brain from primary tumors in other organs.[2] The Central Brain Tumor Registry of the United States reported that primary brain tumors account for around 2% of all cancers, while metastases occur approximately in 10-20% of people with cancerous tumors and are 10 times more frequent than primary brain tumors.[3] The annual frequency of primary brain tumors can reach 19 cases per 100,000 people. The incidence is 3 cases per 100,000 people at less than 4 years of age. The prevalence decreases between 15 and 24 years of age and then increases regularly to a peak of 19 cases per 100,000 people between 65 and 79 years of age.[4]

The World Health Organization (WHO) classifies brain tumors into different types, and each of them may be classified into diverse grades, including neuroepithelial and non-neuroepithelial tumors.[5] The majority of primary tumors of the brain in adulthood are gliomas, with a prevalence of 45% among all brain tumors and 90% of primary brain tumors in elderly patients.[6] Gliomas are classified into 4 grades (I, II, III, and IV) based on the WHO classification. Low-grade gliomas include grades I and II, while high-grade gliomas include grades III and IV. The grade IV glioma is also known as glioblastoma multiforme.[7]

Many studies have demonstrated a higher prevalence of brain cancer in developed countries. Furthermore, the prevalence of brain cancer depends on many factors, such as age, gender, and race. Meningioma and glioblastoma are mostly detected at approximately 65 years of age. However, the other types of brain tumors, such as pilocytic astrocytoma, germ cell, and pineal region tumors are detected at an early age.[8] The prevalence of brain tumors is moderately greater in men as compared to that in women, but meningeal tumors seem to be 2 times as frequent among women. Regarding gliomas, their incidence is higher in men (7.7/100,000) as compared to that in women (5.61/100,000).[9]

---

**Disclosure**. Author have no conflict of interests, and the work was not supported or funded by any drug company.

---

The prevalence of primary brain tumors is higher in Asian, white, and black populations with regard to American and Indian Native race groups. Brain cancers have a 5-year survival rate of approximately 33%. In general, high performance status, young age, and low histopathological grade are positive prognostic characteristics for primary brain tumors.[10]

Therapeutic options are dependent upon the kind of brain tumor, as well as its location and size. Treatments for brain tumors include surgical resection of solitary lesions, stereotactic brain surgery and radiation with or without chemotherapy.[11] Treatment-induced necrosis is a frequent treatment-related condition occurring during the treatment of gliomas, which is usually detected 3 to 12 months post-treatment.[12] Indeed, after high radiation doses, patients usually develop constant or continuous enhancement detected with recurrent tumors (pseudoprogression), radionecrosis and inflammation. These conditions mimic tumor progression or recurrence after remission.[13] Pseudoprogression appears as an increase in the size of the primary tumor or the appearance of a new lesion, thus resembling early progressive tumors.[14] It is evident that misdiagnosis of recurrent brain tumors changes the treatment strategy, which leads potentially to unnecessary repeat surgery or non-effective second-line treatment.[15] Histopathologic technique is the current gold standard to confirm the diagnosis of recurrent brain tumors, but biopsy is dangerous, with many adverse impacts (such as inflammation and hemorrhage).[16] Hence, differentiating tumor recurrence from other types of treatment-related changes is challenging. Consequently, valid, effective and non-invasive imaging techniques are required to improve the post-treatment surveillance of patients.

Due to the disadvantages of histopathology, diverse neuroimaging techniques have been developed for the distinction of recurrent tumors from treatment-related changes. Magnetic resonance imaging (MRI) modalities, such as diffusion-weighted imaging (DWI) and perfusion-weighted imaging (PWI), and nuclear modalities, including positron emission tomography (PET), which can be associated with computed tomography (PET-CT) or magnetic resonance imaging (PET-MRI), are usually used for this purpose.[14]

Nowadays, MRI is the standard neuroimaging modality for follow-up after treatment.[15] Standard MRI is based on the magnetization properties of atomic nuclei. The most common MRI sequences are T1-weighted and T2-weighted scans.[17] Even with the perfect ability to diagnosis brain tumors, the conventional MRI presents some limitations regarding the distinction between

tumor recurrence and non-specific changes, which is especially relevant after therapy.

To surmount these deficiencies, PET based on radioactive amino acids and PWI are suggested as alternative modalities that may supply supplementary pathophysiological evidence to standard MRI. Perfusion-weighted imaging is one of the most broadly used clinical techniques. It is accurate, reliable, and safe, as well as radiation-free. There are 3 types of PWI-dynamic magnetic contrast-enhanced, dynamic contrast-enhanced, and arterial spin labeling.[18] In recent years, PET using radioactive amino acids has been considered a very pertinent modality and is described as clinically helpful for managing patients with brain tumors.[19] Different types of radioactively labeled tracers (such as, 11C-MET, ^{18}F-FDG [fluorine18-fluorodeoxyglucose], ^{18}F-FLT [fluorothymidine], or ^{18}F-FET [fluorine-fluoro-ethyl-tyrosine]) are injected with PET to improve the detection of recurrent brain tumors.[20] The first radiopharmaceutical tracer to be developed was ^{11}C-methyl-L-methionine (MET), and ^{18}F-FDG is the most broadly applied tracer.[21] Nowadays, both of them are considered the best tracers for PET imaging of brain tumors.[22] In summary, imaging findings from PWI and PET may contribute, in addition to MRI, to improve both diagnostic and therapeutic planning, particularly in clinically challenging situations. However, each of these modalities has its disadvantages. Standard MRI does not produce reliable data to distinguish radiation-related changes from true tumor progression, while Magnetic resonance (MR) spectroscopy and PET can provide false positive results regarding recurrent tumors.[23] Despite their significant contribution to better differentiate recurrent tumors from treatment-related conditions, research comparing the effectiveness of PET and PWI is limited.

Therefore, this systematic review and meta-analysis was carried out to evaluate the diagnostic performance of PWI compared to PET for distinction between tumor recurrence and treatment-related changes. Then, we performed a subgroup analysis to investigate the effectiveness of each PET modality and tracer in comparison with PWI.

**Methods.** This study was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.[24] The writing followed the Meta-analysis of Observational Studies in Epidemiology scheme.[25] The Embase, Web of Science, PubMed, the Cochrane library, and CINAHL databases were used to search potentially interesting articles published from database inception until August 2021.

A systematic search was performed by 2 independent reviewers, using the following terms "perfusion MRI" or "perfusion magnetic resonance imaging" or "perfusion-weighted imaging" or "PWI" and "positron emission tomography" or "PET" and "glioma" or "glioblastoma" or "brain tumor" and "recurrent" or "recurrence."

Relevant articles were screened by title and abstract after suppression of duplicates. Articles were included if they described the use of PWI and PET to detect brain tumor recurrence. Then, they were read in full text to verify eligibility.

The inclusion criteria were as follows: i) patients with suspected radiological recurrence at the site of previously irradiated brain tumor; ii) histopathology or clinicoradiological diagnosis used as a reference to differentiate treatment-related effects from recurrent tumors; iii) use of PWI and PET; iv) publications reporting sufficient information on the sensitivity and specificity of each test; and v) studies published as original articles. The exclusion criteria were as follows: i) no full text electronically available; ii) publication in a language other than English; iii) comments, letters, editorials, protocols, guidelines, and review papers; iv) use of other imaging techniques (DWI or conventional MRI); or v) studies with insufficient outcome data.

Two independent reviewers independently retrieved information from the eligible articles following the inclusion and exclusion criteria, and the information was collected on a standardized data sheet that included author name, year, type of study, country, number and age of participants, diagnosis of tumor, time since radiation completed (days), modality and optimal cutoff, type of PET, the follow-up period and the reference technique used to differentiate pseudoprogression from recurrent tumors. The methodologic quality of the included studies was evaluated independently by 2 authors using the Quality Assessment of Diagnostic Accuracy Studies-2 tool, which includes four criteria—"patient selection," "index test," "reference standard," and "flow and timing".[26] The outcomes of interest were the accuracy, sensitivity, and specificity of PET and PWI to detect tumor recurrence.

*Statistical analysis.* In this meta-analysis, accuracy, sensitivity and specificity measures of the best effective parameter were pooled from each article. The statistical analyses were carried out using RevMan Version 5.4 (Cochrane Collaboration, Oxford, United Kingdom). Rate ratios (RRs) with 95% confidence intervals (CIs) were adopted to compare the sensitivity, specificity and accuracy between PWI and PET. A *p* value of <0.05 was considered as the level of significance. The Cochrane

Chi-squared test was conducted to assess heterogeneity among studies, with $p<0.05$ indicating the existence of heterogeneity. The $I^2$ value was used to estimate the impact of heterogeneity on the meta-analysis; $I^2 \geq 50\%$ and $p<0.05$ indicated a moderate to high degree of heterogeneity among pooled studies. When $I^2<50\%$ and $p>0.05$, a fixed effects model was conducted; if not, a random effects design was adopted.[27] Additionally, we carried out subgroup and sensitivity analyses to evaluate the likely cause of heterogeneity. Egger's test was carried out via Statistical Package for Social Sciences version 25 (IBMCorp, Armonk, NY, USA) to evaluate publication bias. This latter was further assessed based on the visual inspection of the symmetry in funnel plots.

**Results.** Database searches identified 3315 articles to be screened, of which 1859 studies were revealed as potentially eligible and retrieved for full text review. Eligibility criteria were met by 14 studies, which were included in this systematic review and meta-analysis. The PRISMA study flowchart is shown in **Figure 1**.

The 14 included studies were published between 2008 and 2021 and distributed among 10 countries.[28-41] Among the 14 articles included in this meta-analysis, 3 were prospective studies and 11 were retrospective studies. The sample size of the included articles varied from 10 to 104 patients and the age varied between 8 and 81 years. Histopathology was the reference standard to detect tumor recurrence. The following 4 types of amino acid tracers were used with PET: $^{18}$F-FDG (7 articles), $^{11}$C-methionine (5 articles), $^{18}$F-FET (2 articles), and fluorodopa (one article). The features of the studies are recapitulated in **Table 1**.

Regarding patient selection, enrollment was cited in all articles. Considering the index test criteria, a specified threshold was mentioned in the majority of the articles. In addition, a low risk of bias was revealed in many articles in terms of flow and timing criteria (75%). Moreover, all studies had a low risk in terms of reference standard, since the diagnosis was based on histopathology. A recapitulation of the risk of bias is presented in **Figure 2**.

Of the 14 included studies, 10 studies reported the accuracy of PWI and PET. The heterogeneity ($\chi^2=17.65$, $p=0.04$, $I^2=49\%$) was high, so a random effects model was adopted. The forest plot showed that the accuracy outcome was not significantly different between PWI and PET (RR=0.94, 95% CI: 0.86-1.02; $p=0.15$) (**Figure 3**).

All the studies reported the sensitivities of both PWI and PET. A random effects model was adopted because the heterogeneity was high ($\chi^2=70.90$,



**Figure 1** - An outline of the PRISMA guidelines used to conduct this meta-analysis.

**Table 1** - Features of included articles (N=14).

| Author name and year | Study design | Country | Period since completion of radiation (month) | Type of tumor | Number of patients |
|---|---|---|---|---|---|
| Cicone et al[28] 2015 | Retrospective | Italy | 3 to 45 | Brain metastases | 42 |
| Dandois et al[29] 2010 | Retrospective | Belgium | 2 | Astrocytic tumours with grades III Astrocytic tumours with grades IV grade III oligoastrocytomas | 28 |
| D'Souza et al[30] 2014 | Prospective | India | 7 to 19 | High-grade gliomas (III-IV) | 29 |
| Estrada et al[31] 2008 | Prospective | Mexico | ND | Choroid plexus carcinoma Anaplastic astrocytoma Glioblastoma multiforme Gliosarcoma Anaplastic oligoastrocytoma | 30 |
| Hatzoglou et al[32] 2016 | Prospective | USA | ≤3 | Gliomas (II to IV) Brain metastases | 53 |
| Hojjati et al[33] 2018 | Retrospective | USA | 2 to 90 | Glioblastoma multiforme | 24 |
| Jabeen et al[34] 2021 | Retrospective | India | 3 to 12 | Glioblastoma multiforme oligodendroglioma (grade II-IV) Anaplastic oligodendro glioma Anaplastic astrocytoma | 48 |
| Kim et al[35] 2010 | Retrospective | Korea | 3 to 91 | Anaplastic astrocytoma Glioblastoma Anaplastic oligodendroglioma | 10 |
| Prat et al[36] 2010 | Retrospective | Spain | ND | Anaplastic astrocytoma Astrocytoma Ependymoma Glioblastoma multiform | 24 |
| Pyka et al[37] 2018 | Retrospective | Germany | 15 | Glioblastoma Anaplastic Astrocytoma, Diffuse astrocytoma Oligodendroglioma Anaplastic oligodendroglioma | 47 |
| Qiao et al[38] 2019 | Retrospective | China | >3 | High-grade tumor (grade III -IV) | 42 |
| Sacconi et al[39] 2016 | Retrospective | USA | ND | Low- and high-grade tumor (grade II to IV) | 20 |
| Seligman et al[40] 2019 | Retrospective | Canada | 2 to 156 | Grade III Grade IV | 41 |
| Steidl et al[41] 2021 | Retrospective | Germany | 6 to 12 | Oligodendroglioma Astrocytoma Astrocytoma Glioblastoma | 104 |

ND: not defined, USA: United States of America

$p<0.00001$, $I^2=79\%$). The forest plot demonstrated that the sensitivity outcome was not significantly different between PWI and PET (RR=0.95, 95% CI: 0.85-1.06; $p=0.32$) (**Figure 4**).

All the studies reported the specificities of both PWI and PET. A random effects model was adopted as the heterogeneity was high ($\chi^2=90.95$, $p<0.00001$, $I^2=84\%$). The forest plot revealed that the specificity outcome was not significantly different between PWI

and PET (RR=1.10, 95% CI: 0.98-1.23; $p=0.12$) (**Figure 5**).

Exploratory subgroup analysis suggested that an only prospective study design was a cause of heterogeneity for the accuracy outcome ($p=0.03$). Regarding sensitivity, all parameters contributed to the heterogeneity, except the ^{18}F-FET and ^{11}C-methionine tracers ($p=0.07$). Similarly, all parameters caused heterogeneity for the

**Table 1** - Features of included articles (N=14) (continuation).

| Author name and year | Age | Number of lesions | Modality and optimal cutoff | The amino acid tracers of PET | PET modality | Follow-up period (month) | Reference standard |
|---|---|---|---|---|---|---|---|
| Cicone et al[28] 2015 | 38–84 | 46 (PET) 37 (PWI) | *SUVLmax/Bkgrmax (rSUV), 1.59 *rCBV, 2.14 | F-DOPA | PET/CT | 6 | Histopathology+clinico-radiological follow-up |
| Dandois et al[29] 2010 | 25- 74 | 33 | *rCBV, 182% *rCBV, 378% | 11C-methionine | PET | 3 to 40 | Histopathology |
| D'Souza et al[30] 2014 | 15-61 | 29 | *SUV, ND *rCBV, 182% | 11C-methionine | PET/CT | 6 to 28 | Histopathology+clinico-radiological follow-up |
| Estrada et al[31] 2008 | 17-77 | 30 | *SUV, ND *rCBV, 1.2 | 18F-FDG | PET/MRI | 6 to 21 | Clinical and radiological criteria |
| Hatzoglou et al[32]2016 | 19–81 | 55 | *SUVratio, 1.2 *Vpratio, 2.1 | 18F-FDG | PET/CT | 6 | Histopathology+clinico-radiological follow-up |
| Hojjati et al[33] 2018 | 34-81 | 28 (PET/MRI) 27 (PWI) 23 (PET/CT) | *r-Mean, 1.47 *CBVmax, 3.32 | 18F-FDG | PET/CT | 8 to 18 | Histopathology+clinico-radiological follow-up |
| Jabeen et al[34] 2021 | 8-71 | 48 | *TBRmax, 1.23 *rCBVratio, 1.38 | 11C-methionine | PET/MRI | 1 to 14 | Histopathology+clinico-radiological follow-up |
| Kim et al[35] 2010 | 31-66 | 10 | *Lmax/Rmax, 2.64 *rCBV, 3.69 | 11C-methionine + 18F-FDG | PET | 6 to 50 | Histopathology+clinical course |
| Prat et al[36] 2010 | 18-70 | 26 | ND | 18F-FDG | PET | 5 | Histopathology+clinico-radiological follow-up |
| Pyka et al[37] 2018 | 42-64 | 63 | *TBR, 2.07 *rCBV, 3.35 | 18F-FET | PET/MRI | 6 | Histopathology + imaging follow-up |
| Qiao et al[38] 2019 | ND | 42 | *TBRSUVmax, 1.85 *rCBVmean, 1.83 | 11C-methionine | PET/CT | 6 | Histopathology+ Clinical follow up |
| Sacconi et al[39] 2016 | 14–74 | 34 | *SUVmean, <4.0 *rCBVmean, <1.74 | 18F-FDG | PET/MRI | 3 to 6 | Histopathology |
| Seligman et al[40] 2019 | 21-79 | 41 | *Whole-tumor SUVmean divided by SUVmean of normal white matter >0.75 *Mean Ktrans of whole tumor divided by mean Ktrans of contralateral brain >4.5 | 18F-FDG | PET/MRI | 6 | Histopathology+clinico-radiological follow-up |
| Steidl et al[41] 2021 | 20–78 | 104 | *Slope, <0.69 *rCBVmax, >2.85 | 18F-FET | PET/MRI | 6 | Histopathology+clinico-radiological follow-up |

ND - not defined, PET - positron emission tomography, MRI - magnetic resonance imaging, CT - computed tomography, PWI - perfusion-weighted imaging, 18F-FDG - 18fluorine-fluorodeoxyglucose, 18F-FET - 18F-fluoro-ethyl-tyrosine, 18F-FLT- (18)Fluorothymidine, CBV - Cerebral Blood Volume, TBR - Tumor to Background Ratio SUV - Standardized Uptake Value, F-DOPA - fluorodopa

specificity outcome, except the prospective study design ($p$=0.44) (**Table 2**). Additionally, we noticed that the 3 outcomes were not significantly different between PWI versus (vs) PET, PWI vs PET/CT, and PWI vs PET/MRI ($p$>0.05 for all). Interestingly, we revealed a significant difference in terms of accuracy and sensitivity when using the 18F-FET tracer ($p$<0.05). Indeed, 18F-FET-PET proved to be more efficient than PWI in differentiating recurrent tumors from treatment-related changes (**Figure 6**).

A leave-one-out sensitivity analysis was conducted to detect the likely cause of heterogeneity in the pooled RR of accuracy, sensitivity, and specificity between PWI and PET. The findings revealed that the outcomes did not differ noticeably, which indicates that this meta-analysis had solid precision. Indeed, the RRs of

**Figure 2 -** Risk of bias items presented as percentages across all articles. PET: positron emission tomography, PWI: perfusion-weighted imaging, CI: confidence interval



**Figure 3 -** Forest plot of the rate ratio of accuracy between perfusion-weighted imaging (PWI) and positron emission tomography (PET). CI: confidence interval



**Figure 4 -** Forest plot of the rate ratio of sensitivity between perfusion-weighted imaging (PWI) and positron emission tomography (PET). CI: confidence interval

**Figure 5** - Forest plot of the rate ratio of sensitivity between perfusion-weighted imaging (PWI) and positron emission tomography (PET). CI: confidence interval



**Figure 6** - Forest plot showing the rate ratio of (**A**) accuracy and (**B**) sensitivity between PWI and positron emission tomography (PET).

accuracy, sensitivity, and specificity ranged from 0.93 (95% CI 0.79-1.01) to 0.98 (95% CI 0.89-1.10), from 0.93 (95% CI 0.80-1.02) to 1.04 (95% CI 0.93-1.17), and from 0.97 (95% CI 0.88-1.17) to 1.13 (95% CI 1.03-1.31), respectively.

We demonstrated no proof of publication bias for all 3 outcomes analyzed by using Egger's regression test ($p>0.05$). Moreover, visual inspection of the funnel plot revealed symmetry (**Figure** 7).

**Discussion.** The present systematic review and meta-analysis comprising 14 articles is, to the best of our knowledge, the first to assess the relative effectiveness of PWI and PET in the distinction between early recurrent tumors and changes related to treatment. Discriminating between treatment change and tumor recurrence has been a subject of expanded medical interest using diverse neuroimaging techniques.

Consistent with previous research articles on the distinction between true tumor recurrence and treatment-related conditions, this systematic review and meta-analysis included articles of patients with suspected radiological progression at the site of previously irradiated brain tumors, at an interval not

**Figure 7** - Funnel plot showing no publication bias in terms of (**A**) accuracy, (**B**) sensitivity, and (**C**) specificity among the studies.

only <3 months but also >3 months after radiation therapy. In fact, treatment-related conditions are a wide class that consists of diverse well-defined clinical units regrouping pseudoprogression, as well as radiation necrosis and mixed response.[42] Pseudoprogression usually appears weeks to 3 months after the achievement of treatment, while radiation necrosis occurs in most cases 18-24 months to years afterward.[43] Hence, distinction of recurrent tumors from treatment-related alterations is challenging, since both disorders presented similar neurological signs.[44] Consequently, the prompt detection of recurrent tumors (within 3 months) allows physicians to choose between changes in chemotherapy and repeat surgery in order to ameliorate the patient's

course. Standard MRI techniques have low efficiency, as revealed by Taghipour Zahir et al,[45] who revealed that MRI yielded a limited specificity of 25%.[45] Many studies have discussed the limitations of conventional imaging techniques in differentiating tumor progression/recurrence and immunotherapy responses in order to highlight the need for developing advanced imaging methods to overcome these limitations.[46,47]

Consequently, PWI, and PET have been used for their important role in differentiating recurrent tumors from treatment-related changes. Diverse research has evaluated the effect of amide proton transfer-weighted MRI or MR spectroscopy, investigating particular imaging parameters as important predictors of tumor recurrence.

In the present meta-analysis including 14 studies, PET and PWI were found to have the same effectiveness in distinguishing true tumor progression from treatment-related changes after radiation treatment, regardless of the modality or amino acid tracer used with PET. Positron emission tomography and PWI are promising techniques, but comparative studies on their effectiveness have shown heterogenous results in terms of early progression. Steidl et al[41] reported that PET could differentiate glioma progression from treatment-related changes with a specificity of just 62% against 100% for PWI.[41] Similarly, Seligman et al[41] revealed that the best-performing PET and PWI cutoffs achieved a specificity of 56% and 89%, respectively, indicating that PWI is more efficient than PET in detecting recurrent tumors.[40] In this context, Patel et al[48] demonstrated that PWI-derived thresholds differentiating true tumor progression from other conditions revealed high accuracy. Obviously, additional standardization and investigation are needed before adopting any specific PWI strategy, due to the significant variability in optimal reported thresholds.[48]

On the other hand, some studies showed that PET was more efficient than PWI. For example, Cicone et al[28] revealed that PET was a highly accurate tool for differentiating brain radionecrosis from recurrent brain metastases after stereotactic radiosurgery, with a sensitivity of 93.3% and a specificity of 90.9%, which is higher than those yielded by PWI (86.7% and 68.2%, respectively).[28] Similar findings have been highlighted by Sacconi et al[39] who demonstrated that PET seems to outperform PWI in terms of specificity (89.7% vs 74%).

Regarding the amino acid tracers used with PET, we have noticed that ^{18}F-FET-PET was more efficient than PWI in terms of accuracy and sensitivity. A previous meta-analysis demonstrated that 18F-FDG

and ^{11}C-MET PET seemed to possess a relatively high accuracy for detecting the recurrence of gliomas.[49] Yet, studies investigating ^{18}F-FET and ^{18}F-FLT cited good sensitivity, especially for high-grade tumors.[50,51] ^{18}F-FET and ^{18}F-FLT are newly discovered PET tracers. Over the past years, they have been investigated in clinical use only. Only some studies have evaluated the diagnostic accuracy of these tracers. Although pertinent findings have been cited, supplementary validations are required. Recently, de Zwart et al[52] carried out a meta-analysis to assess the diagnostic performance of 11 PET tracers for the distinction of tumor recurrence from radiation-related alteration in high-grade tumors. The findings obtained showed that ^{18}F-FET and ^{11}C-MET had a higher sensitivity than ^{18}F-FDG in the distinction of recurrent tumors from radiation-related alterations. However, the evidence for the remaining tracers was limited.

The major advantage of PWI in comparison with PET in brain tumors include whole brain coverage and simpler post-processing methodology.[53] In addition, the software used to postprocess data yielded by PWI is broadly accessible and quite easy to use. Perfusion modalities present to the user the capacity to investigate the brain's microvasculature from a different perspective. This may provide a real evaluation of tumor angiogenesis. Furthermore, perfusion MRI is a very safe imaging method, unlike PET which presents a risk of radiation exposure.[54] The main findings were that costs were significantly lower for PWI compared with PET in the evaluation of brain tumors. Perfusion-weighted imaging was economically attractive, especially because of fewer invasive processes, whereas PET was considered an expensive imaging test with a higher price and no notable difference in terms of sensitivity and specificity compared with PWI. [55,56] Consequently, PWI as a non-invasive, convenient and less expensive modality, seems to be the preferred imaging strategy in post-treatment surveillance of brain tumors.

***Study limitation.*** There are limited number of studies that compare other tracers or PET vs different neuroimaging techniques (such as, PWI). Thereby, research articles conducting head-to-head comparisons between PET tracers and alternative MR imaging techniques (such as, MR spectroscopy, DWI, and PWI or between different PET tracers) are particularly needed.

In the present study, we carried out literature searches in 5 different databases. The principal strong items of this article are the large scale of studies and considerable number of participants analyzed. Although unpublished articles were not included in our study, the funnel plot did not show a publication bias. Additionally, the sensitivity analyses showed that the estimated RR of accuracy, sensitivity and specificity outcomes were reliable and not effected when a single study was omitted.

***Study limitation.*** This meta-analysis relates to the elevated rate of heterogeneity between the articles. Regarding the subgroup analysis, heterogeneity could be likely due to differences in study design, PET modalities, and amino acid tracer used. These differences caused major difficulties in synthesizing all available studies. Hence, considerable heterogeneity, which is expected in meta-analysis studies, can alter the interpretability of results.[57] Consequently, the findings of the present work have to be analyzed with attentiveness.

In conclusion, PET and PWI show comparable accuracy, specificity and sensitivity in differentiating recurrent tumors from radiation-related alterations. Taking into account the advantages of PWI compared to PET in terms of safety, availability and cost, PWI seems to be more favorable than PET for the follow-up of patients.

These techniques presented conflicting results between some studies. Provided that the neuroimaging distinction between recurrent tumors and treatment-related changes represents a real challenge and has an impact on the choice of therapeutic strategy, supplementary works with larger sample sizes are required to produce more significant findings.

## References

1. Kheirollahi M, Dashti S, Khalaj Z, Nazemroaia F, Mahzouni P. Brain tumors: special characters for research and banking. *Adv Biomed Res* 2015; 4: 4.

2. Perkins A, Liu G. Primary brain tumors in adults: diagnosis and treatment. *Am Fam Physician* 2016; 93: 211-217.

3. Lin X, DeAngelis LM. Treatment of brain metastases. *J Clin Oncol* 2015; 33: 3475-3484.

4. Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. *J Nucl Med* 2000; 41: 1861-1867.

5. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol* 2007; 114: 97-109.

6. Gállego Pérez-Larraya J, Delattre J. Management of elderly patients with gliomas. *Oncologist* 2014; 19: 1258-1267.

7. Wesseling P, Capper D. WHO 2016 classification of gliomas. *Neuropathol Appl Neurobiol* 2018; 44: 139-150.

8. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. *Neuro Oncol* 2013; 15: ii1–ii56.

9. Tamimi AF, Juweid M. Epidemiology and outcome of glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma. Brisbane (AU): Codon Publications; 2017.

10. Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. *JAMA Oncol* 2018; 4: 1254-1262.

11. Minniti G, Filippi AR, Osti MF, Ricardi U. Radiation therapy for older patients with brain tumors. *Radiat Oncol* 2017; 12: 101.

12. Winter SF, Loebel F, Loeffler J, Batchelor TT, Martinez-Lage M, Vajkoczy P, et al. Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology. *Neuro Oncol* 2019; 21: 1118-1130.

13. Ellingson BM, Chung C, Pope WB, Boxerman JL, Kaufmann TJ. Pseudoprogression, radionecrosis, inflammation or true tumor progression? Challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. *J Neurooncol* 2017; 134: 495-504.

14. Wang L, Wei L, Wang J, Li N, Gao Y, Ma H, et al. Evaluation of perfusion MRI value for tumor progression assessment after glioma radiotherapy: a systematic review and meta-analysis. *Medicine* 2020; 99: e23766.

15. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-Oncology Working Group. *J Clin Oncol* 2010; 28: 1963-1972.

16. Malone H, Yang J, Hershman DL, Wright JD, Bruce JN, Neugut AI. Complications following stereotactic needle biopsy of intracranial tumors. *World Neurosurg* 2015; 84: 1084-1089.

17. Villanueva-Meyer JE, Mabray MC, Cha S. Current clinical brain tumor imaging. *Neurosurgery* 2017; 81: 397-415.

18. Testud B, Brun G, Varoquaux A, Hak JF, Appay R, Le Troter A, et al. Perfusion-weighted techniques in MRI grading of pediatric cerebral tumors: efficiency of dynamic susceptibility contrast and arterial spin labeling. *Neuroradiology* 2021; 63: 1353-1366.

19. Langen KJ, Heinzel A, Lohmann P, Mottaghy FM, Galldiks N. Advantages and limitations of amino acid PET for tracking therapy response in glioma patients. *Expert Rev Neurother* 2020; 20: 137-146.

20. Treglia G, Muoio B, Trevisi G, Mattoli MV, Albano D, Bertagna F, et al. Diagnostic performance and prognostic value of PET/CT with different tracers for brain tumors: a systematic review of published meta-analyses. *Int J Mol Sci* 2019; 20: 4669.

21. Långström B, Antoni G, Gullberg P, Halldin C, Malmborg P, Någren K, et al. Synthesis of L- and D-[methyl-11C] methionine. *J Nucl Med* 1987; 28: 1037-1040.

22. Galldiks N, Langen KJ, Pope WB. From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors? *Neuro Oncol* 2015; 17: 1434-1444.

23. Mitsuya K, Nakasu Y, Horiguchi S, Harada H, Nishimura T, Bando E, et al. Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery. *J Neurooncol* 2010; 99: 81-88.

24. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *BMJ* 2009; 339: b2700.

25. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. *JAMA* 2000; 283: 2008-2012.

26. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med* 2011; 155: 529-536.

27. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. *Res Synth Method* 2010; 1: 97-111.

28. Cicone F, Minniti G, Romano A, Papa A, Scaringi C, Tavanti F, et al. Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery. *Eur J Nucl Med Mol Imaging* 2015; 42: 103-111.

29. Dandois V, Rommel D, Renard L, Jamart J, Cosnard G. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of treated high-grade gliomas: preliminary results in clinical practice. *J Neuroradiol* 2010; 37: 89-97.

30. D'Souza MM, Sharma R, Jaimini A, Panwar P, Saw S, Kaur P, et al. 11C-MET PET/CT and advanced MRI in the evaluation of tumor recurrence in high-grade gliomas. *Clin Nucl Med* 2014; 39: 791-798.

31. Estrada G, González-Maya L, Celis-López MA, Gavito J, Lárraga-Gutiérrez JM, Salgado P, et al. Diagnostic approach in suspected recurrent primary brain tumors using 18FDG-PET/MRI, perfusion MRI, visual and quantitative analysis, and three dimensional stereotactic surface projections. First experience in Mexico. *Rev Esp Med Nucl* 2008; 27: 329-339.

32. Hatzoglou V, Yang TJ, Omuro A, Gavrilovic I, Ulaner G, Rubel J, et al. A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. *Neuro Oncol* 2016; 18: 873-880.

33. Hojjati M, Badve C, Garg V, Tatsuoka C, Rogers L, Sloan A, et al. Role of FDG-PET/MRI, FDG-PET/CT, and dynamic susceptibility contrast perfusion MRI in differentiating radiation necrosis from tumor recurrence in glioblastomas. *J Neuroimaging* 2018; 28: 118-125.

34. Jabeen S, Arbind A, Kumar D, Singh PK, Saini J, Sadashiva N, et al. Combined amino acid PET-MRI for identifying recurrence in post-treatment gliomas: together we grow. *Eur J Hybrid Imaging* 2021; 5: 15.

35. Kim YH, Oh SW, Lim YJ, Park CK, Lee SH, Kang KW, et al. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI. *Clin Neurol Neurosurg* 2010; 112: 758-765.

36. Prat R, Galeano I, Lucas A, Martínez JC, Martín M, Amador R, et al. Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas. *J Clin Neurosci* 2010; 17: 50-53.

37. Pyka T, Hiob D, Preibisch C, Gempt J, Wiestler B, Schlegel J, et al. Diagnosis of glioma recurrence using multiparametric dynamic 18F-fluoroethyl-tyrosine PET-MRI. *Eur J Radiol* 2018; 103: 32-37.

38. Qiao Z, Zhao X, Wang K, Zhang Y, Fan D, Yu T, et al. Utility of dynamic susceptibility contrast perfusion-weighted MR imaging and 11 C-methionine PET/CT for differentiation of tumor recurrence from radiation injury in patients with high-grade gliomas. *AJNR Am J Neuroradiol* 2019; 40: 253-259.

39. Sacconi B, Raad RA, Lee J, Fine H, Kondziolka D, Golfinos JG, et al. Concurrent functional and metabolic assessment of brain tumors using hybrid PET/MR imaging. *J Neurooncol* 2016; 127: 287-293.

40. Seligman L, Kovanlikaya I, Pisapia DJ, Naeger DM, Magge R, Fine HA, et al. Integrated PET-MRI for glioma surveillance: perfusion-metabolism discordance rate and association with molecular profiling. *Am J Roentgenol* 2019; 212: 883-891.

41. Steidl E, Langen KJ, Hmeidan SA, Polomac N, Filss CP, Galldiks N, et al. Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes. *Eur J Nucl Med Mol Imaging* 2021; 48: 1956-1965.

42. Lee J, Wang N, Turk S, Mohammed S, Lobo R, Kim J, et al. Discriminating pseudoprogression and true progression in diffuse infiltrating glioma using multi-parametric MRI data through deep learning. *Sci Rep* 2020; 10: 20331.

43. Yu FF, Rapalino O. Treated Gliomas. In: Neuroradiology. Amsterdam: Elsevier; 2019. p. 136-152.

44. Chao ST, Ahluwalia MS, Barnett GH, Stevens GHJ, Murphy ES, Stockham AL, et al. Challenges with the diagnosis and treatment of cerebral radiation necrosis. *Int J Radiat Oncol Biol Phys* 2013; 87: 449-457.

45. Taghipour Zahir S, Rezaei sadrabadi M, Dehghani F. Evaluation of diagnostic value of CT scan and MRI in brain tumors and comparison with biopsy. *Iran J Ped Hematol Oncol* 2011; 1: 121-125.

46. Aquino D, Gioppo A, Finocchiaro G, Bruzzone MG, Cuccarini V. MRI in glioma immunotherapy: evidence, pitfalls, and perspectives. *J Immunol Res* 2017; 2017: 5813951.

47. Young RJ, Gupta A, Shah AD, Graber JJ, Zhang Z, Shi W, et al. Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. *Neurology* 2011; 76: 1918-1924.

48. Patel P, Baradaran H, Delgado D, Askin G, Christos P, John Tsiouris A, et al. MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis. *Neuro Oncol* 2017; 19: 118-127.

49. Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. *AJNR Am J Neuroradiol* 2013; 34: 944-950.

50. Mehrkens JH, Pöpperl G, Rachinger W, Herms J, Seelos K, Tatsch K, et al. The positive predictive value of O-(2-[18F] fluoroethyl)-l-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. *J Neurooncol* 2008; 88: 27-35.

51. Spence AM, Muzi M, Link JM, O'Sullivan F, Eary JF, Hoffman JM, et al. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3′-deoxy-3′-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. *Mol Imaging Biol* 2009; 11: 343-355.

52. de Zwart PL, van Dijken BRJ, Holtman GA, Stormezand GN, Dierckx RAJO, Jan van Laar P, et al. Diagnostic accuracy of PET tracers for the differentiation of tumor progression from treatment-related changes in high-grade glioma: a systematic review and metaanalysis. *J Nucl Med* 2020; 61: 498-504.

53. Vagal A, Vossough A, Lev MH, Wintermark M. Central nervous system infarction. In: Handbook of neuro-oncology neuroimaging. Amsterdam: Elsevier; 2016. p. 89-98.

54. Essig M, Shiroishi MS, Nguyen TB, Saake M, Provenzale JM, Enterline D, et al. Perfusion MRI: the five most frequently asked technical questions. *Am J Roentgenol* 2013; 200: 24-34.

55. Li Z, Zhou P, Xiong Z, Ma Z, Wang S, Bian H, et al. Perfusion-weighted magnetic resonance imaging used in assessing hemodynamics following superficial temporal artery-middle cerebral artery bypass in patients with moyamoya disease. *Cerebrovasc Dis* 2013; 35: 455-460.

56. Berger M, Gould MK, Barnett PG. The cost of positron emission tomography in six United States Veterans Affairs Hospitals and two academic medical centers. *Am J Roentgenol* 2003; 181: 359-365.

57. Imrey PB. Limitations of meta-analyses of studies with high heterogeneity. *JAMA Netw Open* 2020; 3: e1919325.